California’s $3 billion effort has just begun (2007) — and this article from the San Jose Mercury News points out that profits are long term, not short term, because:
- Ethical/moral arguments surrounding stem cell research
- So little is known, basic research is the first recipient of funds
- Risky process of developing product keeps investors at bay
- Two companies, Geron and Advanced Cell, hold many of the patents for human embryonic stem cell research and associated technologies.
However, there are eternal optimists:
“You’ll see more companies forming around embryonic work,” said Gregory Bonfiglio, managing partner of Palo Alto-based Proteus Venture Partners, which plans to invest in such firms. “This technology will fundamentally change health care.”
